Staphylococcus aureus News and Research

RSS
Staphylococcus aureus is a spherical bacterium (coccus) which on microscopic examination appears in pairs, short chains, or bunched, grape-like clusters. These organisms are Gram-positive. Some strains are capable of producing a highly heat-stable protein toxin that causes illness in humans.
New way to combat bacterial biofilm formation with titanium encrusted with gold nanoparticles

New way to combat bacterial biofilm formation with titanium encrusted with gold nanoparticles

Covenant and Sartori medical centers deploy TRU-D SmartUVC superbug-slaying robot

Covenant and Sartori medical centers deploy TRU-D SmartUVC superbug-slaying robot

Xenex testifies before U.S. House of Representatives on effectiveness of UV disinfection system in reducing HAI rates

Xenex testifies before U.S. House of Representatives on effectiveness of UV disinfection system in reducing HAI rates

Personalized antibiotic therapy can help fight antibiotic-resistant infections

Personalized antibiotic therapy can help fight antibiotic-resistant infections

Current sequencing protocols overlook DNA crucial to bacterial virulence

Current sequencing protocols overlook DNA crucial to bacterial virulence

Cubist Pharmaceuticals' SIVEXTRO receives FDA approval for treatment of ABSSSI

Cubist Pharmaceuticals' SIVEXTRO receives FDA approval for treatment of ABSSSI

Infection prevention and control guidance prioritizes strategies to combat MRSA

Infection prevention and control guidance prioritizes strategies to combat MRSA

Synthetic, Enterome partner to study effects of beta-lactam antibiotics on gastrointestinal microflora

Synthetic, Enterome partner to study effects of beta-lactam antibiotics on gastrointestinal microflora

S. pneumoniae is major cause of severe pneumonia in Gambian children

S. pneumoniae is major cause of severe pneumonia in Gambian children

Cubist Pharmaceuticals publishes positive results from Phase 3 clinical trial of SIVEXTRO

Cubist Pharmaceuticals publishes positive results from Phase 3 clinical trial of SIVEXTRO

NEJM publishes results from SOLO I Phase 3 clinical trial of ORBACTIV for ABSSSI

NEJM publishes results from SOLO I Phase 3 clinical trial of ORBACTIV for ABSSSI

New single-dose antibiotic is as effective as twice-daily infusion given for up to 10 days

New single-dose antibiotic is as effective as twice-daily infusion given for up to 10 days

New antibiotic proves effective in treating serious bacterial skin and skin-structure infections

New antibiotic proves effective in treating serious bacterial skin and skin-structure infections

Superbugs decrease among patients after adding UVD to cleaning regimen

Superbugs decrease among patients after adding UVD to cleaning regimen

MGH researchers test novel approach to disinfecting wounds in animal study

MGH researchers test novel approach to disinfecting wounds in animal study

Disease-causing bacteria can linger in airplane cabins for days, says study

Disease-causing bacteria can linger in airplane cabins for days, says study

LA BioMed researcher receives APIC Award for Publication Excellence

LA BioMed researcher receives APIC Award for Publication Excellence

Study: E-cigarettes appear to increase virulence of drug- resistant and life-threatening bacteria

Study: E-cigarettes appear to increase virulence of drug- resistant and life-threatening bacteria

New expert guidance encourages healthcare institutions to implement prevention efforts infectious diarrhea

New expert guidance encourages healthcare institutions to implement prevention efforts infectious diarrhea

Researchers identify novel vancomycin-resistant MRSA superbug in Brazil

Researchers identify novel vancomycin-resistant MRSA superbug in Brazil

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.